Mineralocorticoid Receptor Antagonists in End Stage Renal Disease

NCT01691053 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

OTHER

Sponsor class

Conditions

End Stage Renal Disease / Hemodialysis

Interventions

DRUG: Spironolactone
DRUG: Placebo

Sponsor

Wuerzburg University Hospital

Collaborators

[object Object]
[object Object]